Irritable Bowel Syndrome - Pipeline Review, H2 2017

Date: November 7, 2017
Pages: 154
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I6691E4F088EN
Leaflet:

Download PDF Leaflet

Irritable Bowel Syndrome - Pipeline Review, H2 2017
Irritable Bowel Syndrome - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2017, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 11, 7, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Irritable Bowel Syndrome - Overview
Irritable Bowel Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
4D Pharma PLC
Alfa Wassermann SpA
Allergan Plc
Aptevo Therapeutics Inc
Ardelyx Inc
Astellas Pharma Inc
ConSynance Therapeutics Inc
Cosmo Pharmaceuticals NV
Dong-A ST Co Ltd
Eisai Co Ltd
Enterome Bioscience SA
GlaxoSmithKline Plc
ImmuneBiotech AB
Innovative Med Concepts LLC
Ironwood Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Napo Pharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
Scythian Biosciences Corp
SK Biopharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Vitality Biopharma Inc
Irritable Bowel Syndrome - Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APVO-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7147 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bedoradrine sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Blautix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Canchew Plus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crofelemer DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTI-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-6952 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-2508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EB-420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3179106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide DR2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-4006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lyrica - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relenopride hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00202730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00310941 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCY-002P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solabegron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Irritable Bowel Syndrome - Dormant Projects
Irritable Bowel Syndrome - Discontinued Products
Irritable Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Oct 19, 2017: Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug
Oct 16, 2017: Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting
Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG 2017
Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 12, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at the World Congress of Gastroenterology at American College of Gastroenterology
Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Oct 03, 2017: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D
Sep 28, 2017: RedHill Biopharma to Announce Top-Line Results from BEKINDA 12 mg Phase II Study for IBS-D on October 3rd, 2017
Jul 17, 2017: RedHill Biopharma Announces Last Patient Visit in BEKINDA Phase II Study for IBS-D
Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
Jun 07, 2017: Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation
May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect on Pain at Digestive Disease Week 2017
May 01, 2017: Allergan to Present Linzess and Linaclotide Delayed Release Data at Digestive Disease Week 2017
May 01, 2017: Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at Digestive Disease Week
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Irritable Bowel Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H2 2017
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann SpA, H2 2017
Irritable Bowel Syndrome - Pipeline by Allergan Plc, H2 2017
Irritable Bowel Syndrome - Pipeline by Aptevo Therapeutics Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H2 2017
Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H2 2017
Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H2 2017
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2017
Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2017
Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H2 2017
Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts LLC, H2 2017
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by Pfizer Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H2 2017
Irritable Bowel Syndrome - Pipeline by Scythian Biosciences Corp, H2 2017
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H2 2017
Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2017
Irritable Bowel Syndrome - Dormant Projects, H2 2017
Irritable Bowel Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017
Irritable Bowel Syndrome - Dormant Projects, H2 2017 (Contd..2), H2 2017
Irritable Bowel Syndrome - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Irritable Bowel Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4D Pharma PLC
Alfa Wassermann SpA
Allergan Plc
Aptevo Therapeutics Inc
Ardelyx Inc
Astellas Pharma Inc
ConSynance Therapeutics Inc
Cosmo Pharmaceuticals NV
Dong-A ST Co Ltd
Eisai Co Ltd
Enterome Bioscience SA
GlaxoSmithKline Plc
ImmuneBiotech AB
Innovative Med Concepts LLC
Ironwood Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Napo Pharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
Scythian Biosciences Corp
SK Biopharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Synergy Pharmaceuticals Inc
Synthetic Biologics Inc
Vitality Biopharma Inc
Skip to top


Ask Your Question

Irritable Bowel Syndrome - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: